Edition:
United Kingdom

ImmunoGen Inc (IMGN.OQ)

IMGN.OQ on NASDAQ Stock Exchange Global Select Market

6.24USD
22 Oct 2018
Change (% chg)

$-1.19 (-16.02%)
Prev Close
$7.43
Open
$7.26
Day's High
$7.26
Day's Low
$6.01
Volume
911,484
Avg. Vol
581,561
52-wk High
$13.41
52-wk Low
$4.81

Chart for

About

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor... (more)

Overall

Beta: 2.22
Market Cap(Mil.): $768.71
Shares Outstanding(Mil.): 112.22
Dividend: --
Yield (%): --

Financials

  IMGN.OQ Industry Sector
P/E (TTM): -- 85.41 33.64
EPS (TTM): -1.21 -- --
ROI: -63.15 0.21 14.27
ROE: -- 1.17 15.99

BRIEF-ImmunoGen Reports Q1 Loss Per Share $0.30

* IMMUNOGEN REPORTS RECENT PROGRESS AND FIRST QUARTER 2018 OPERATING RESULTS

04 May 2018

BRIEF-Immunogen Completes Interim Analysis For Forward I Phase 3 Trial Of Mirvetuximab Soravtansine

* IMMUNOGEN ANNOUNCES SUCCESSFUL COMPLETION OF INTERIM ANALYSIS FOR FORWARD I PHASE 3 TRIAL OF MIRVETUXIMAB SORAVTANSINE IN PLATINUM-RESISTANT OVARIAN CANCER

26 Apr 2018

Earnings vs. Estimates